Antibiotics for the treatment of irritable bowel syndrome
about
Profile of rifaximin and its potential in the treatment of irritable bowel syndromeIrritable bowel syndrome: a concise review of current treatment conceptsSafety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome.Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancerThe comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.Complementary and alternative medicines in irritable bowel syndrome: an integrative view.Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats.Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats.Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
P2860
Q26829363-9B548132-61B9-4530-800F-719C15ED64FDQ26996547-2D6C63DF-B4CF-40D4-BED8-CB35BDF63117Q33958376-02F920D3-A13D-4C27-A975-2799A3C098C6Q34433294-CCBDBE0E-502D-4550-97EF-1036B3006815Q34454007-D355DBB5-D113-4663-ADB8-7177E11F8545Q35971357-CF7B7856-C3D5-4012-98E2-FFCAAB5F5651Q36825040-DACC02BA-3CE1-455F-A546-D3EC1D6D7E76Q37504612-4ED71CA0-EC16-4F78-B8E6-25F0276B39B1Q37564122-96BE3226-DE35-4914-91F4-333E24599918Q37581337-53B633FA-91F7-465E-8CAD-7C5667D920EFQ38375923-F4053BE2-B5A0-4044-8D8A-FD8386F7CAEAQ47110969-CBF2B0AD-90B5-45DF-A113-1CD24FDFE05DQ55439068-065E55E8-ED78-43D0-A720-D75BEA403AA0Q57070200-F6CB2F9B-A6A6-4635-B90C-1F3B68940765
P2860
Antibiotics for the treatment of irritable bowel syndrome
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antibiotics for the treatment of irritable bowel syndrome
@ast
Antibiotics for the treatment of irritable bowel syndrome
@en
type
label
Antibiotics for the treatment of irritable bowel syndrome
@ast
Antibiotics for the treatment of irritable bowel syndrome
@en
prefLabel
Antibiotics for the treatment of irritable bowel syndrome
@ast
Antibiotics for the treatment of irritable bowel syndrome
@en
P2093
P2860
P1476
Antibiotics for the treatment of irritable bowel syndrome
@en
P2093
Gillian M Barlow
Mark Pimentel
Robert J Basseri
Stacy Weitsman
P2860
P304
P577
2011-07-01T00:00:00Z